• Users Online: 352
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2020  |  Volume : 8  |  Issue : 2  |  Page : 48-52

Nintedanib for the treatment of idiopathic pulmonary fibrosis: An Indian perspective


1 Department of Respiratory Medicine, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, Uttarakhand, India
2 Department of Respiratory Medicine, Base Hospital Delhi Cantt, Delhi, India
3 Department of Respiratory Medicine, King George Medical University, Lucknow, Uttar Pradesh, India
4 Department of Pharmacology, Dr Ram Manohar Lohia Institute of Medical Sciences, Gomti Nagar, Lucknow, Uttar Pradesh, India

Correspondence Address:
Dr. Kislay Kishore
MD, Graded Specialist (Respiratory Medicine), Department of Respiratory Medicine, Base Hospital, Delhi Cantt, Delhi 110010
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jacp.jacp_35_19

Rights and Permissions

Idiopathic pulmonary fibrosis (IPF) is a chronic disease associated with progressive deterioration of lung function and ultimately death. Until recent past, no drug therapy was approved for the management of IPF and patients either received symptomatic treatment or were enrolled in clinical trials. Since 2014, two new drugs with anti-fibrotic potential have been approved following positive outcomes in large-scale clinical trials. Nintedanib is the latest drug in this category and has recently been launched in India. Here we present a review about nintedanib, covering its mechanism of action, efficacy, adverse effect profile, cost effectiveness and implications in the Indian setting.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed354    
    Printed20    
    Emailed0    
    PDF Downloaded66    
    Comments [Add]    

Recommend this journal